Omicron-specific PCR test for new Variant of Concern
Our Omicron-specific PCR test assay for the fast identification of the new omicron variant of SARS-CoV-2 is designed for rapid determination of the new variant already in the screening-PCR for SARS-CoV-2. The assay also detects the BA.2 variant.
VoXcreen and VoXident qPCR assays
Our Omicron-specific PCR test robustly targets distinct deletions in the genome of the new Omicron Variant of Concern. It thereby efficiently singles out the omicron variant for determination.
The assay is available as single- or multiplex assay.
For fastest results, our new multiplex assay “VoXcreen-DO” differentiates in a single PCR reaction between the Delta- and the Omicron variant.
Since both variants together represent nearly 100% in most countries, the assay directly detects the VoCs of nearly all positive samples in a single PCR. For the few non-Delta and non-Omicron variants, our “Alpha, Beta, Gamma” assay can be performed as follow-up PCR.
In addition, the assay targets the N1-Gene, common in all SARS-CoV-2 using a WHO-recommended assay design. Therefore, the both variants are identified with the recommended dual-target stratgy. The assay also contains an internal isolation control (RP).
While current tests need at least two separate PCR reactions and often also genome sequencing for the specific identification of the Omicron VoC, our test identifies Omicron reliably in a single PCR reaction. This safes time and liberates PCR-capacities that are critically needed.
Currently, mostly S-gene drop out or S-gene target failure “SGTF” is used to find potential cases of omicron. Since this test does not discriminate between Omicron or Alpha variant, it is not sure if it is really Omicron and additional tests have to be performed. This is cumbersome: the sample has to be searched for in the fridge (usually by hand) and there is a risk of sample-mixing, also the RNA can already be degraded due to additional freeze-thaw cycles. Also, the “failure” of a test is not a proper diagnostic approach since it may as well be caused by another reason such as partly degraded RNA. Therefore, a positive proof is preferred. Our PCR assays target highly specific mutations onyl described in the Omicron VoC and in the Delta VoC for a clear and precise identification of the different VoCs- during the screening PCR.
Concerning the BA.2 Variant – falsely denominated “stealth” variant
The subvariant predecessor of Omicron called BA.2 is often falsely denominated as “stealth” variant. The reason for this is that it does not carry a mutation, (del69/70) which is present in alpha and omicron. This mutation leads to a “drop-out” of a specific PCR product targeting the s-gene, that is used in some widely used PCR tests. This drop-out or “failure” was used to identify the alpha variant and now the omicron variant and is known as “S-gene target failure” (SGTF) (see above). However, the failure can be also caused by other reasons e.g. by degraded RNA, a bad PCR batch or other reasons, also the method cannot distinguish between the Alpha and the Omicron variant. Therefore we do not use the SGTF but a POSITIVE signal caused by a specific PCR product that can only be generated in the omicron variant. In the case of the BA.2 our test will identify the universal target. For a specific determination, our BA.2 specific assay can be used.
New version of our VoXcreen assay: VoXcreen BA.1& BA.2
The latest version of our VoXcreen assay discriminates between BA.1 and BA.2 directly during the screening. Due to the fast replacement of the delta variant, this assay is screening for the two most relevant variants that are currently driving the pandemic.
Our Omicron-specific assay is also available as single assay with fluorophores of your choice and as primer-probe mix.
For all other SARS-CoV-2 related products including PCR- tests for specific mutations to determine the Lambda, Mu, C.1.2 as well as other VoCs and VoIs please click HERE.
All assays are currently for Research Use Only, certification process is ongoing and our kits are already in use after internal testing of certified laboratories.
About the Omicron-VoC
The Omicron variant (B.1.1.529 is the latest Variant of Concern (VoC) of SARS-CoV-2, declared the 26th of November by the WHO. It was first identified in South Africa and was considered as VoC because of several local, steeply increasing number of infections. Moreover, it outnumbered the already highly infectious Delta variant in the concerned areas and therefore was quickly regarded as VoC by the WHO. The variant has is now the dominant variant in all countries.
The Omicron variant carries numerous mutations some of which are known from the alpha variant and has accumulated a number of additional mutations in the spike gene. Therefore, it may be carrying epitopes that differ from those against which the current vaccines are designed.
Cat. Nr. 031522-VoXcreen-NDORP; 96-10.000 reactions (For N1, Delta and Omicron + internal ctrl.)
Cat. Nr. 031522-VoXIdent-DORP; 96-10.000 reactions (For Omicron and Delta detection + internal ctrl.)
Cat. Nr. 031522-VoXIdent-ADORP; 96-10.000 reactions (For Alpha, Delta and Omicron detection + internal ctrl.)
Cat. Nr. 031522-VoXIdent-ORP; 96-10.000 reactions (For Omicron detection + internal ctrl.)
For more information or to purchase our kits or services, please write us an e-mail (email@example.com), or call us at +49 69 95739710.
From tissue to results- full service or kits for all your samples
Gel Free smallRNASeq kit
TrueQuant (UMI) Adaptor kits for up to 386 samples
16s-RNA Seq Kit for Microbiomes